Risperidone for schizophrenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 22 Mar 2023: Trial registered, NCT05779241
  2. 13 Apr 2023: Trial started, NCT05779241

The trials

NCT05779241: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

State
Completed
Phase
Phase 3
People
83 taking part
Started
13 Apr 2023
Primary completion
3 Nov 2023
Arms
LYN-005 Containing 15-mg Risperidone, LYN-005 Containing 45-mg Risperidone
Results
None posted
  1. 22 Mar 2023: Trial registered
  2. 13 Apr 2023: Trial started
  3. 1 Dec 2023: Trial completed

NCT06878833: A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
18 Apr 2025
Primary completion
31 Dec 2026
Arms
Open Label (OL) Cohort, Double Blind (DB) Cohort: LYN-005
Results
None posted
  1. 17 Mar 2025: Trial registered
  2. 8 Apr 2025: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as LYN-005, LYN-005 (risperidone), Perseris, Risperdal, Risvan, Rykindo, Risperidone 1 MG, Uzedy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.